Author
@Quantumup1 Quantumup1
grade Cx.com/Quantumup1 ↗
Real-time, attributive firehose of sell-side biotech analyst actions and catalysts
Quote-tweets and relays Wall Street analyst actions on biote
trader score
·
hit rate
·
mean α
·
signals 14d
44
Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY.
Their picks, scored
Not yet in the scored-bets universe (fewer than 20 scoreable calls). Their last-14d mentions, direction-adjusted, have moved +2.4% since posting (mean over 13 mentions with price data).
Recent signals15receipts included
| date (PT) | ticker | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|---|
| 2026-08-28 | BHVN | @Quantumup1 | +0.40 | TD Cowen reiterates Buy and a $30 target, citing attractive deal economics and runway. | · | tweet ↗ |
| 2026-08-28 | SYRE | @Quantumup1 | +0.40 | Guggenheim reiterates SYRE as a Buy and Top Pick with a $130 target. | · | tweet ↗ |
| 2026-08-28 | RVMD | @Quantumup1 | +0.40 | Guggenheim raises RVMD's target to $275 from $240 and maintains Buy. | — | tweet ↗ |
| 2026-08-28 | RVMD | @Quantumup1 | +0.40 | UBS raises RVMD's target to $265 from $220 and keeps Buy after approval. | — | tweet ↗ |
| 2026-08-28 | RARE | @Quantumup1 | +0.40 | Wells Fargo raises RARE's target to $50 from $46 and maintains Overweight. | · | tweet ↗ |
| 2026-08-27 | IMRX | @Quantumup1 | +0.40 | H.C. Wainwright reiterated Buy and a $14 12-month target on IMRX. | · | tweet ↗ |
| 2026-08-27 | AMLX | @Quantumup1 | +0.40 | Guggenheim raised AMLX's price target to $57 from $55 on improved probability of success. | -6.6% | tweet ↗ |
| 2026-08-27 | ODTX | @Quantumup1 | +0.40 | H.C. Wainwright initiated ODTX at Buy with a $44 target. | · | tweet ↗ |
| 2026-08-27 | MIRM | @Quantumup1 | +0.40 | Citizens reiterated Market Outperform and a $137 target on MIRM. | · | tweet ↗ |
| 2026-08-27 | RVMD | @Quantumup1 | +0.40 | Oppenheimer raised RVMD's target to $260 from $230 and reiterated Outperform. | -6.0% | tweet ↗ |
| 2026-08-26 | BHVN | @Quantumup1 | +0.35 | Expects the Kv7 sale to reduce Biohaven headcount by about 35%. | · | tweet ↗ |
| 2026-08-26 | BHVN | @Quantumup1 | -0.10 | Raymond James retains Strong Buy but cuts Biohaven's target to $30 from $50. | · | tweet ↗ |
| 2026-08-26 | BHVN | @Quantumup1 | +0.40 | Argues the Kv7 sale could reduce Biohaven cash burn by one-half to three-quarters. | · | tweet ↗ |
| 2026-08-26 | BHVN | @Quantumup1 | +0.35 | Argues the sold Kv7 program was the main driver of Biohaven's cash burn. | · | tweet ↗ |
| 2026-08-26 | AXGN | @Quantumup1 | +0.40 | Truist initiates Axogen at Buy with a $60 price target. | · | tweet ↗ |
Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.